Production of unique antibacterial and antitumor drugs launched in Belarus

A modernised workshop for production of unique drugs – all developed by Belarusian scientists – has opened at Belarusian State University’s Unitechprom company

The facility enjoys modern equipment and fully complies with international GMP standards. Drugs that have no analogues in the world will be produced here. Among them are anti-adhesive Antispike, antibacterial Foscelantan and antitumor Prospidelong. All medicines have been developed by scientists of the BSU’s Institute of Physical and Chemical Problems.

BSU Rector Andrei Korol commented, “The opening of such a workshop is one of the most important stages of the evolutionary development of Unitechprom, which closely co-operates with our Institute of Physical and Chemical Problems, the Chemical Faculty and the Biological Faculty. Actually, it is a scientific and educational conglomerate, which unites our alumni and undergraduates. We now have modern facilities to produce three drugs which are of an extremely important value for our healthcare system. For example, Antispike prevents the formation of adhesions after surgical interventions, and it has also antiviral and bactericidal effects – being used locally after surgical intervention. Its use prevents the development of leucocytosis and has no negative effect on the blood clotting system.”

Foscelantan is another innovative drug – designed to accelerate the regeneration of damaged tissues. It is a bio-absorbable plate for external use. The remedy accelerates the healing of wounds with boils, abscesses, carbuncles, fistulas, thermal burns, and trophic ulcers. In addition, the drug is indispensable for treatment of surgical sutures, incised, stab wounds and abrasions, as well as prevention of infectious complications.

Prospidelong bioabsorbable gel is intended for treatment of stomach cancer, and it is used as local chemotherapy. Importantly, it is 20 times cheaper than a similar drug produced in the United States.

As noted by Mr. Korol, previously, such medicines were not produced in Belarus, but it is now possible not to rely on import supplies, to improve the effectiveness of treatment and to reduce the length of patients’ stay in polyclinics and hospitals.

In turn, Sergei Kazakevich, the General Director of the Managing Company of the Belpharmprom Holding RUE, emphasised that it is too early to talk about large-scale production volumes. According to him, another point matters, “Unitechprom is a small company, but its importance cannot be underestimated. Innovations and developments are concentrated here, and the products of the future are made.”